| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/14737175.6.10.1495 |
| P698 | PubMed publication ID | 17078789 |
| P2093 | author name string | Herbert B Newton | |
| P2860 | cites work | Tight junctions of the blood-brain barrier: development, composition and regulation | Q24292730 |
| Astrocyte-endothelial interactions at the blood-brain barrier | Q28131675 | ||
| The JAM family of junctional adhesion molecules | Q28205895 | ||
| Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates | Q30335770 | ||
| Epidemiology of primary brain tumors: current concepts and review of the literature | Q30501715 | ||
| Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials | Q30686073 | ||
| Current epidemiological trends and surveillance issues in brain tumors | Q30703391 | ||
| Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas | Q30885145 | ||
| Convection-enhanced delivery of targeted toxins for malignant glioma | Q31038118 | ||
| Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme | Q33358912 | ||
| Development of neuropeptide drugs that cross the blood-brain barrier | Q33569277 | ||
| Drug transport to brain with targeted liposomes | Q33569479 | ||
| Blood-brain barrier biology and methodology | Q33797055 | ||
| Nanoparticulate systems for brain delivery of drugs | Q33938252 | ||
| Blood-brain barrier drug targeting: the future of brain drug development | Q33976325 | ||
| Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems | Q33985125 | ||
| Drug transport to brain with targeted nanoparticles | Q33985140 | ||
| Molecular biology of the blood-brain barrier | Q33986161 | ||
| A review of nanocarrier-based CNS delivery systems | Q33995027 | ||
| A family of drug transporters: the multidrug resistance-associated proteins. | Q34004952 | ||
| Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability | Q34057451 | ||
| Brain Drug Targeting and Gene Technologies | Q34432102 | ||
| Molecular physiology and pathophysiology of tight junctions in the blood–brain barrier | Q34446031 | ||
| Targeting Neurotherapeutic Agents Through the Blood-Brain Barrier | Q34492689 | ||
| Nanoparticle technology for drug delivery across the blood-brain barrier | Q34540557 | ||
| Drug and gene targeting to the brain with molecular Trojan horses | Q34742814 | ||
| Local treatment of brain tumors with targeted chimera cytotoxic proteins | Q34798727 | ||
| The role of drug transporters at the blood-brain barrier | Q34988105 | ||
| DAB389EGF fusion protein therapy of refractory glioblastoma multiforme | Q35060905 | ||
| Effect of pegylation on pharmaceuticals | Q35075776 | ||
| Convection-enhanced delivery of macromolecules in the brain | Q35091232 | ||
| Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport. | Q35130192 | ||
| Pegylation: engineering improved biopharmaceuticals for oncology | Q35200818 | ||
| Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways | Q35576159 | ||
| Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis | Q35641225 | ||
| Recombinant toxins as novel therapeutic agents | Q35671038 | ||
| Brain endothelial cells as pharmacological targets in brain tumors | Q35913889 | ||
| Brain drug delivery of small molecules using immunoliposomes | Q35947016 | ||
| Blood-brain barrier genomics, proteomics, and new transporter discovery | Q36045436 | ||
| Advantages of liposomal delivery systems for anthracyclines | Q36045808 | ||
| Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies | Q36045816 | ||
| Convection-enhanced delivery in clinical trials | Q36052811 | ||
| Cell biology of the neurovascular unit: implications for drug delivery across the blood-brain barrier | Q36083831 | ||
| Occludin: structure, function and regulation | Q36093750 | ||
| Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle | Q36118431 | ||
| Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours | Q36150422 | ||
| Targeted delivery across the blood-brain barrier | Q36316725 | ||
| The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. | Q36320804 | ||
| Neuroscience nanotechnology: progress, opportunities and challenges | Q36350205 | ||
| Development of the blood-brain barrier: a historical point of view | Q36377906 | ||
| Claudins and epithelial paracellular transport | Q36387912 | ||
| Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents | Q36395924 | ||
| Controlled-release microchips | Q36460857 | ||
| Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas | Q36481960 | ||
| High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours | Q36691999 | ||
| Immunotoxins and central nervous system neoplasia | Q36725728 | ||
| Liposome-mediated therapy of intracranial brain tumors in a rat model | Q36880242 | ||
| Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier | Q37521936 | ||
| Interstitial Chemotherapy with Carmustine-loaded Polymers for High-grade Gliomas: A Randomized Double-blind Study | Q38557135 | ||
| Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group | Q38573324 | ||
| Paclitaxel nanoparticles for the potential treatment of brain tumors | Q40513384 | ||
| Outwitting the Blood-Brain Barrier for Therapeutic Purposes: Osmotic Opening and Other Means | Q40859254 | ||
| Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor | Q40881449 | ||
| Transporting therapeutics across the blood-brain barrier | Q41105360 | ||
| Hydrogen bonding potential as a determinant of the in vitro and in situ blood-brain barrier permeability of peptides | Q41485081 | ||
| Drug entry into the brain | Q41729326 | ||
| The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. | Q42011060 | ||
| Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin | Q43824344 | ||
| Synthesis of pegylated immunonanoparticles | Q44144588 | ||
| Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma | Q44800304 | ||
| Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging | Q44826956 | ||
| Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. | Q44918948 | ||
| Entrapment of small molecules and nucleic acid-based drugs in liposomes | Q45274488 | ||
| Antisense gene therapy of brain cancer with an artificial virus gene delivery system | Q45731908 | ||
| Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker | Q46958091 | ||
| Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles | Q48003121 | ||
| Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties | Q48087236 | ||
| Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality | Q48132856 | ||
| Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig | Q48133104 | ||
| Glycation increases the permeability of proteins across the blood-nerve and blood-brain barriers | Q48149103 | ||
| Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults | Q48303492 | ||
| Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration | Q48469485 | ||
| (131)I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma | Q48586802 | ||
| Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors | Q48587395 | ||
| Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas | Q48674565 | ||
| Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. | Q55473881 | ||
| Improved bioavailability to the brain of glycosylated Met-enkephalin analogs | Q56114253 | ||
| P433 | issue | 10 | |
| P921 | main subject | brain tumor | Q233309 |
| drug delivery | Q1392806 | ||
| P304 | page(s) | 1495-1509 | |
| P577 | publication date | 2006-10-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders | Q15760319 |
| P1476 | title | Advances in strategies to improve drug delivery to brain tumors | |
| P478 | volume | 6 |
| Q39277953 | A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity |
| Q38830917 | A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation |
| Q38095485 | Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles |
| Q41709059 | Application of dual targeting drug delivery system for the improvement of anti-glioma efficacy of doxorubicin |
| Q46610511 | Assessment of a balloon-tipped catheter modified for intracerebral convection-enhanced delivery |
| Q38133554 | Cell-penetrating Peptide-mediated therapeutic molecule delivery into the central nervous system |
| Q38511670 | Control of the blood-brain barrier function in cancer cell metastasis |
| Q38401892 | Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor |
| Q37392913 | Exploiting macrophages as targeted carrier to guide nanoparticles into glioma |
| Q39157025 | Glioma therapy using tumor homing and penetrating peptide-functionalized PEG–PLA nanoparticles loaded with paclitaxel |
| Q36922469 | Heat shock protein 70-binding protein 1 is highly expressed in high-grade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds brain tumor cell surfaces |
| Q38537217 | Intraarterial drug delivery for glioblastoma mutiforme: Will the phoenix rise again? |
| Q33911283 | Molecular targeting of glioblastoma: Drug discovery and therapies |
| Q37538776 | NanoART, neuroAIDS and CNS drug delivery |
| Q48209715 | Nanomedicine and neurodegenerative disorders: so close yet so far. |
| Q51562724 | Nanomedicine: The Future for Advancing Medicine and Neuroscience |
| Q36119579 | Peptide-mediated targeting of liposomes to TrkB receptor-expressing cells |
| Q38807560 | Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimer |
| Q37076360 | Polymeric nanoparticles for the drug delivery to the central nervous system |
| Q54978120 | Substance P-modified human serum albumin nanoparticles loaded with paclitaxel for targeted therapy of glioma. |
| Q38232202 | The blood-brain barrier: structure, function and therapeutic approaches to cross it. |
| Q39431870 | Two-Order Targeted Brain Tumor Imaging by Using an Optical/Paramagnetic Nanoprobe across the Blood Brain Barrier |
| Q36787338 | Use of nanoparticles for drug delivery in glioblastoma multiforme |
Search more.